INM
InMed Pharmaceuticals Inc.·Healthcare
1.70
1.163%(−0.02)
Market OpenLast Updated: — ET
52W L: $0.5752W H: $7.98
INM NEWS
globenewswire.com
7h ago
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
seekingalpha.com
2d ago
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
globenewswire.com
May 20
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating InMed Pharmaceuticals, Inc. (NASDAQ: INM ) related to its merger with Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately 1.51% of the combined company. Is it a fair deal?
globenewswire.com
May 19
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (Nasdaq – INM) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Mentari Therapeutics, Inc. InMed shareholders are expected to own approximately 1.51% of the combined company.
gurufocus.com
May 19
/C O R R E C T I O N -- InMed Pharmaceuticals/
/C O R R E C T I O N -- InMed Pharmaceuticals/ PR Newswire VANCOUVER, BC and SAN FRANCISCO, May 19, 2026
gurufocus.com
May 19
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon clos
